Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers - Seite 2
About BDC-3042
Bolt Biotherapeutics’ myeloid-modulating antibody, BDC-3042, leverages the power of myeloid cells to stimulate anti-tumor activity. It agonizes Dectin-2, an immune-activating pattern recognition
receptor expressed by tumor-associated macrophages (TAMs) which are frequently found in the tumor microenvironment. TAMs play a key role in establishing an immunosuppressive tumor microenvironment
that is conducive to tumor survival and progression. By agonizing Dectin-2, BDC-3042 activates TAMs to produce pro-inflammatory cytokines and chemokines and repolarizes TAMs into immunostimulatory
macrophages. In addition, BDC-3042 induces expression of key antigen presentation machinery, which helps to expand tumor-reactive T cells and elicit anti-tumor immunity.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company leveraging the immune system for a better way to treat cancer. The company is developing novel immunotherapies using an approach
that teaches the immune system to recognize and kill cancer in a way that is immediately personalized to each patient. Its pipeline candidates are built on the Company’s deep expertise in myeloid
biology and cancer drug development and include BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC) being evaluated in a Phase 2 trial, and BDC-3042, a
myeloid-modulating agonist antibody targeting Dectin-2, being evaluated in a Phase 1 trial. Bolt Biotherapeutics is also developing multiple Boltbody ISACs in strategic collaborations with leading
biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Lesen Sie auch
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information
currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding the advancement and success of our clinical
trials and any potential future patent term extensions or adjustments, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other
similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates
and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These
statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical
development or receive required regulatory approvals within expected timelines or at all; clinical trials may not demonstrate the desired safety, potency or other product characteristics described
or assumed in this press release; and such product candidates may not be beneficial to patients or become commercialized. These risks are not exhaustive. Except as required by law, we assume no
obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new
information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is
included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022. These filings, when
available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.